282 related articles for article (PubMed ID: 30712414)
1. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
[TBL] [Abstract][Full Text] [Related]
2. Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer.
No JH; Jeon YT; Park IA; Kim YB; Kim JW; Park NH; Kang SB; Han JY; Lim JM; Song YS
Gynecol Oncol; 2011 Apr; 121(1):8-12. PubMed ID: 21276607
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma.
Wang Z; Zheng T; Wu Q; Wang J; Wu C; Wang J
Neoplasma; 2012; 59(2):137-41. PubMed ID: 22248270
[TBL] [Abstract][Full Text] [Related]
4. Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma.
Wang W; Wen Q; Xu L; Xie G; Li J; Luo J; Chu S; Shi L; Huang D; Li J; Fan S
PLoS One; 2014; 9(8):e106098. PubMed ID: 25165983
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
[TBL] [Abstract][Full Text] [Related]
9. Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance.
Zhou L; Yuan D; Zhang ZG; Liang ZY; Zhou WX; Yang JY; Jiang SH; Lu J; Zhang TP; You L; Guo JC; Zhao YP
Cancer Lett; 2017 Jun; 395():45-52. PubMed ID: 28279716
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma.
Li SH; Chen CH; Lu HI; Huang WT; Tien WY; Lan YC; Lee CC; Chen YH; Huang HY; Chang AY; Lin WC
Surgery; 2015 Mar; 157(3):570-80. PubMed ID: 25726316
[TBL] [Abstract][Full Text] [Related]
11. Expression of phosphorylated mTOR and its regulatory protein is related to biological behaviors of ameloblastoma.
Li N; Zhong M; Song M
Int J Clin Exp Pathol; 2012; 5(7):660-7. PubMed ID: 22977662
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
14. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.
Kasajima A; Pavel M; Darb-Esfahani S; Noske A; Stenzinger A; Sasano H; Dietel M; Denkert C; Röcken C; Wiedenmann B; Weichert W
Endocr Relat Cancer; 2011 Feb; 18(1):181-92. PubMed ID: 21159731
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer.
Ma BL; Shan MH; Sun G; Ren GH; Dong C; Yao X; Zhou M
Mol Med Rep; 2015 Oct; 12(4):5246-54. PubMed ID: 26151180
[TBL] [Abstract][Full Text] [Related]
16. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma.
Qu Y; Zhao R; Wang H; Chang K; Yang X; Zhou X; Dai B; Zhu Y; Shi G; Zhang H; Ye D
Sci Rep; 2016 Mar; 6():23594. PubMed ID: 27026382
[TBL] [Abstract][Full Text] [Related]
18. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
[TBL] [Abstract][Full Text] [Related]
20. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Tomek K; Wagner R; Varga F; Singer CF; Karlic H; Grunt TW
Mol Cancer Res; 2011 Dec; 9(12):1767-79. PubMed ID: 21970855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
